American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

Author: Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B.

Source: J Oral Maxillofac Surg.

Year: 2009

Comment:

The authors of this 2009 update note, "Discontinuation of oral bisphosphonate therapy in patients with BRONJ has been associated with gradual improvement in clinical disease.68 Discontinuation of oral bisphosphonates for 6 to 12 months can result in either spontaneous sequestration or resolution after debridement surgery."

Abstract / Excerpt:

“Bisphosphonate-related osteonecrosis of the jaw (BRONJ) adversely affects the quality of life, producing significant morbidity in afflicted patients. Strategies for the treatment of patients with, or at risk of, BRONJ were set forth in the American Association of Oral and Maxillofacial Surgeons (AAOMS) Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws (Position Paper) and approved by the Board of Trustees in September 2006.”

Citation:

Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.  J Oral Maxillofac Surg. 2009; 67(5 Suppl):2-12.